Search clinical trials for: Cyclophosphamide,Fludarabine

Total 4221 results

German CLL Study Group

Completed

Fludarabine and Cyclophosphamide in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Chronic Lymphocytic Leukemia or Waldenstrom's Macroglobulinemia

Chronic Lymphocytic Leukemia

Canada, Germany
National Heart, Lung, and Blood Institute (NHLBI)

Terminated

Peripheral Stem Cell Transplant in Treating Patients With High-Risk Leukemia

Leukemia | Chronic Myeloproliferative Disorders | Myelodysplastic/Myeloproliferative Diseases

United States
National Cancer Institute (NCI)

Completed

3-AP and Fludarabine in Treating Patients With Myeloproliferative Disorders, Chronic Myelomonocytic Leukemia, or Accelerated Phase or Blastic Phase Chronic Myelogenous Leukemia

Primary Myelofibrosis | Polycythemia Vera | Essential Thrombocythemia | Chronic Myelomonocytic Leukemia | Accelerated Phase Chronic Myelogenous Leukemia | Relapsing Chronic Myelogenous Leukemia | Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative | Philadelphia Chromosome Negative Chronic Myelogenous... and other conditions

United States
M.D. Anderson Cancer Center
Bristol-Myers Squibb; National Cancer Institute (NCI); Iovance Biotherapeutics

Active, not recruiting

Autologous Tumor Infiltrating Lymphocytes MDA-TIL in Treating Patients With Recurrent or Refractory Ovarian Cancer, Colorectal Cancer, or Pancreatic Ductal Adenocarcinoma

Malignant Solid Neoplasm | Metastatic Colorectal Adenocarcinoma | Stage IV Colorectal Cancer AJCC v8 | Stage IVA Colorectal Cancer AJCC v8 | Stage IVB Colorectal Cancer AJCC v8 | Stage IVC Colorectal Cancer AJCC v8 | Platinum-Resistant Ovarian Carcinoma | Metastatic Pancreatic Ductal Adenocarcinoma | Metastatic Ovarian Carcinoma and other conditions

United States
Fred Hutchinson Cancer Center
SignalOne Bio, Inc.

Terminated

Genetically Engineered Cells (MAGE-A1-specific T Cell Receptor-transduced Autologous T-cells) and Atezolizumab for the Treatment of Metastatic Triple Negative Breast Cancer, Urothelial Cancer, or Non-small Cell Lung Cancer

Metastatic Lung Non-Small Cell Carcinoma | Anatomic Stage IV Breast Cancer AJCC v8 | Stage IV Lung Cancer AJCC v8 | Metastatic Malignant Solid Neoplasm | Metastatic Urothelial Carcinoma | Metastatic Triple-Negative Breast Carcinoma

United States
Genta Incorporated

Completed

Genasense® (Oblimersen Sodium), Fludarabine, and Rituximab in Subjects With Chronic Lymphocytic Leukemia

Chronic Lymphocytic Leukemia

United States
University College, London

Completed

Evaluation of CAR19 T-cells as an Optimal Bridge to Allogeneic Transplantation (COBALT)

Diffuse Large B-Cell Lymphoma

United Kingdom
Xinqiao Hospital of Chongqing

Unknown

Anti-GPC3 CAR-T for Treating GPC3-positive Advanced Hepatocellular Carcinoma (HCC)

Hepatocellular Carcinoma

China
University of Birmingham

Active, not recruiting

A Comparison of Reduced Dose Total Body Irradiation (TBI) and Cyclophosphamide With Fludarabine and Melphalan Reduced Intensity Conditioning in Adults With Acute Lymphoblastic Leukaemia (ALL) in Complete Remission. (ALL-RIC) (ALL-RIC)

Acute Lymphoblastic Leukemia

United Kingdom
Baylor College of Medicine
Cancer Prevention Research Institute of Texas; The Methodist Hospital Research... and other collaborators

Active, not recruiting

Her2 Chimeric Antigen Receptor Expressing T Cells in Advanced Sarcoma

Sarcoma

United States
Kite, A Gilead Company

Active, not recruiting

Study of Brexucabtagene Autoleucel (KTE-X19) in Participants With Relapsed/Refractory Mantle Cell Lymphoma (Cohort 3) (ZUMA-2)

Relapsed/Refractory Mantle Cell Lymphoma

United States, France, Spain, United Kingdom, Netherlands, Germany
GlaxoSmithKline
Merck Sharp & Dohme LLC

Terminated

Letetresgene Autoleucel Engineered T Cells Alone and in Combination With Pembrolizumab in NY-ESO-1 Positive Multiple Myeloma

Neoplasms

United States
Mie University
Fiverings Co., Ltd.; Shionogi; Takara Bio Inc.; Statcom Co. Ltd.

Completed

Investigator Initiated Phase 1 Study of TBI-1201

Solid Tumors

Japan
Mie University
Fiverings Co., Ltd.; Shionogi; Takara Bio Inc.; Statcom Co. Ltd.

Unknown

Investigator Initiated Phase 1 Study of TBI-1301

Solid Tumors

Japan
David Rizzieri
Eleos, Inc.

Terminated

EL625 in Persistent Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Lymphoma, Small Lymphocytic | Leukemia, Lymphocytic, Chronic

United States
Targazyme, Inc.

Unknown

Study of ASC-101 in Patients With Hematologic Malignancies Who Receive Dual-cord Umbilical Cord Blood Transplantation

Lymphoma | Leukemia | Hodgkin's Lymphoma | Transplantation Infection | Myelodysplastic Syndrome (MDS) | Non-Hodgkin's Lymphoma (NHL) | Blood And Marrow Transplantation

United States
National Cancer Institute (NCI)
Eastern Cooperative Oncology Group; NCIC Clinical Trials Group; SWOG Cancer Research...

Completed

Fludarabine and Rituximab With or Without Lenalidomide or Cyclophosphamide in Treating Patients With Symptomatic Chronic Lymphocytic Leukemia

Stage I Chronic Lymphocytic Leukemia | Stage II Chronic Lymphocytic Leukemia | Stage III Chronic Lymphocytic Leukemia | Stage IV Chronic Lymphocytic Leukemia

United States, Canada
M.D. Anderson Cancer Center

Active, not recruiting

A PHASE IB STUDY OF IMMUNOTHERAPY WITH EX VIVO PRE-ACTIVATED AND EXPANDED CB-NK CELLS IN COMBINATION WITH CETUXIMAB, IN COLORECTAL CANCER PATIENTS WITH MINIMAL RESIDUAL DISEASE (MRD)

Colon Cancer | Resected Stage

United States
University of Chicago

Completed

Combined Haploidentical-Cord Blood Transplantation for Adults and Children

Lymphoma | Leukemia | Multiple Myeloma | Myelodysplastic Syndrome

United States
The Affiliated Hospital of the Chinese Academy...

Completed

HLA-mismatched MST vs HLA-matched NST for AML in Intermediate-risk

Acute Myeloid Leukemia

China
OHSU Knight Cancer Institute
National Cancer Institute (NCI); medac GmbH

Completed

Treosulfan and Fludarabine in Treating Younger Patients Who Are Undergoing a Donor Stem Cell Transplant for Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Myelodysplastic Syndrome

Myelodysplastic Syndromes | Leukemia

United States
National Cancer Institute (NCI)

Not yet recruiting

Anti-CD19 Chimeric Antigen Receptor T-Cell Immunotherapy for Chronic Lymphocytic Leukemia (CLL)

Leukemia, Lymphocytic, Chronic, B-Cell | B-Cell Chronic Lymphocytic Leukemia | B-Lymphocytic Leukemia, Chronic

United States
University of California, San Francisco
Parker Institute for Cancer Immunotherapy; The V Foundation; Alliance for Cancer...

Recruiting

Genetically Modified Cells (KIND T Cells) for the Treatment of HLA-A*0201-Positive Patients With H3.3K27M-Mutated Glioma (PNOC018)

Diffuse Midline Glioma, H3 K27M-Mutant

United States
The Affiliated Hospital of Xuzhou Medical University
Xuzhou Medical University; IIT MediTech Co. Ltd

Recruiting

Study Of B7H3 CAR-T Cells in Treating Advanced Liver Cancer

Hepatocellular Carcinoma

China
Dana-Farber Cancer Institute
Secura Bio, Inc.

Active, not recruiting

A Phase 1b/2 Study of IPI-145 Plus FCR in Previously Untreated, Younger Patients With CLL

Chronic Lymphocytic Leukemia

United States
Precision BioSciences, Inc.

Terminated

A Dose-escalation Study to Evaluate the Safety and Clinical Activity of PBCAR269A, With or Without Nirogacestat, in Study Participants With Relapsed/Refractory Multiple Myeloma

Relapsed/Refractory Multiple Myeloma

United States
Dana-Farber Cancer Institute
Kite, A Gilead Company

Active, not recruiting

Axi-cel in CNS Lymphoma

Lymphoma | Lymphoma Cns

United States
Genentech, Inc.

Completed

A Study of Obinutuzumab (GA101; RO5072759) in Combination With Chemotherapy in Participants With Previously Untreated Chronic Lymphocytic Leukemia (CLL) (GALTON)

Lymphocytic Leukemia, Chronic

United States
St. Petersburg State Pavlov Medical University

Completed

GVHD Prophylaxis With Post-transplantation Bendamustine in Refractory Leukemia

Acute Myeloid Leukemia | Leukemia, Acute Lymphoblastic | Mixed-Lineage Acute Leukemias

Russian Federation
Genzyme, a Sanofi Company

Completed

Fludarabine (Fludara®) Plus Alemtuzumab (CAMPATH®, MabCampath®) vs Fludarabine Alone in B-Cell Chronic Lymphocytic Leukemia (B-CLL) Patients

B-Cell Chronic Lymphocytic Leukemia

Sweden, United States, Croatia, Canada, Ukraine, Austria, Bulgaria, France, Germany, Greece, Italy, Poland, Portugal, Romania, Russian Federation
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Completed

Total-Body Irradiation, Thiotepa, and Fludarabine in Treating Young Patients Who Are Undergoing a Donor Stem Cell Transplant for Hematologic Cancer

Myelodysplastic Syndromes | Leukemia

United States
Sanofi

Completed

Study of Docetaxel in Breast Cancer Patients

Breast Neoplasms

Italy
University of Alabama at Birmingham

Completed

Fludarabine / Total Body Irradiation Regimen for ALLO HCT in Acute Lymphoblastic Leukemia (FluTBI)

Adult Lymphoblastic Lymphoma

United States
Beijing 302 Hospital

Not yet recruiting

Combination of ATG-based Conditioning Regimen and PTCy for GVHD Prevention in Allo-HSCT After PD-1 Blockade

Hematological Malignancies | Graft-versus-host Disease
Northside Hospital, Inc.

Recruiting

Reduced Intensity Fludarabine and TBI Prior to Haplo-Identical Transplantation

Hematologic Malignancy

United States
Colorado Blood Cancer Institute

Unknown

Fludarabine and 400 CGY Total Body Irradiation for Recipients of HLA-Matched or Mis-Matched Family or Unrelated Donor Hematopoietic Stem Cell Transplants Who Have Rejected Their First Allogeneic Stem Cell Transplant

Graft Failure

United States
Hideho Okada, MD, PhD
National Cancer Institute (NCI); California Institute for Regenerative Medicine...

Recruiting

Anti-EGFRvIII synNotch Receptor Induced Anti-EphA2/IL-13Ralpha2 CAR (E-SYNC) T Cells

Glioblastoma | Recurrent Glioblastoma | EGFR Gene Mutation | MGMT-Unmethylated Glioblastoma

United States
H. Lee Moffitt Cancer Center and Research Institute
Bristol-Myers Squibb; Iovance Biotherapeutics, Inc.

Active, not recruiting

Ipilimumab With Lymphodepletion Plus Adoptive Cell Transfer and High Dose IL-2 in Melanoma Mets Pts

Metastatic Melanoma

United States
Mayo Clinic

Recruiting

Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors (PNeoVCA)

Metastatic Renal Cell Carcinoma | Anatomic Stage III Breast Cancer AJCC v8 | Anatomic Stage IIIA Breast Cancer AJCC v8 | Anatomic Stage IIIB Breast Cancer AJCC v8 | Anatomic Stage IIIC Breast Cancer AJCC v8 | Prognostic Stage III Breast Cancer AJCC v8 | Prognostic Stage IIIA Breast Cancer AJCC v8 and other conditions

United States
Academic and Community Cancer Research United
National Cancer Institute (NCI)

Active, not recruiting

Multi-epitope Folate Receptor Alpha Peptide Vaccine, GM-CSF, and Cyclophosphamide in Treating Patients With Triple Negative Breast Cancer

Triple-Negative Breast Carcinoma | Stage IB Breast Cancer AJCC v7 | Stage II Breast Cancer AJCC v6 and v7 | Stage IIA Breast Cancer AJCC v6 and v7 | Stage IIB Breast Cancer AJCC v6 and v7 | Stage III Breast Cancer AJCC v7 | Stage IIIA Breast Cancer AJCC v7 | Stage IIIB Breast Cancer AJCC v7 | Stage... and other conditions

United States
University of Louisville

Withdrawn

A Phase I Study to Examine the Toxicity of Allogeneic Stem Cell Transplantation for Relapsed or Therapy Refractory Ewing Sarcoma (ASCT)

Ewing Sarcoma

United States
St. Jude Children's Research Hospital

Recruiting

Study of CD19-directed Allogeneic Memory T-cell Therapy for Relapsed/Refractory CD19+ Leukemia

Pediatric ALL | Acute Lymphoblastic Leukemia, in Relapse | Acute Lymphoblastic Leukemia, Refractory

United States
UNC Lineberger Comprehensive Cancer Center
National Institutes of Health (NIH)

Recruiting

Phase I Study of Autologous CAR T-Cells Targeting the B7-H3 Antigen in Recurrent Epithelial Ovarian

Epithelial Ovarian Cancer

United States
St. Jude Children's Research Hospital

Active, not recruiting

Evaluation of CD19-Specific CAR Engineered Autologous T-Cells for Treatment of Relapsed/Refractory CD19+ Acute Lymphoblastic Leukemia

Acute Lymphoblastic Leukemia, in Relapse | Acute Lymphoblastic Leukemia, Refractory

United States
Celgene

Completed

A Study to Evaluate the Safety of bb2121 in Subjects With High Risk, Newly Diagnosed Multiple Myeloma (NDMM) (KarMMa-4)

Multiple Myeloma

United States
National Cancer Institute (NCI)

Completed

T Cells Expressing a Fully-human AntiCD19 Chimeric Antigen Receptor for Treating B-cell Malignancies

Lymphoma, B-Cell | Lymphoma, Non-hodgkins

United States
Roswell Park Cancer Institute
National Cancer Institute (NCI)

Active, not recruiting

Gene-Modified T Cells With or Without Decitabine in Treating Patients With Advanced Malignancies Expressing NY-ESO-1

Metastatic Melanoma | Advanced Malignant Solid Neoplasm | Unresectable Melanoma | Clinical Stage III Cutaneous Melanoma AJCC v8 | Pathologic Stage IIIB Cutaneous Melanoma AJCC v8 | Pathologic Stage IIIC Cutaneous Melanoma AJCC v8 | Pathologic Stage IIID Cutaneous Melanoma AJCC v8 | Pathologic Stage... and other conditions

United States
Fate Therapeutics

Recruiting

FT522 With Rituximab in Relapsed/Refractory B-Cell Lymphoma (FT522-101)

Relapsed/Refractory B-Cell Lymphoma

United States
Massachusetts General Hospital
Ossium Health, Inc.; ITB-Med LLC

Recruiting

Delayed Tolerance Through Mixed Chimerism

Kidney Failure | Kidney Transplant; Complications | Chimera

United States
Kite, A Gilead Company
Genentech, Inc.

Completed

Study of Safety and Efficacy of KTE-C19 in Combination With Atezolizumab in Adults With Refractory Diffuse Large B-Cell Lymphoma (DLBCL) (ZUMA-6)

Refractory Diffuse Large B Cell Lymphoma

United States

Search clinical trials for: Cyclophosphamide,Fludarabine

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Nigeria

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations